BeiGene Approved to Market Xgeva for Bone Metastases in China

Beijing's BeiGene announced China approval to market Xgeva ® (denosumab) to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. Previously, the drug was approved in China for giant cell tumor of the bone (GCTB) in which surgery was not possible. In 2019, BeiGene acquired China rights to Xgeva as part of its $2.7 billion deal with Amgen, which included China rights to 23 Amgen oncology assets. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: AMGN) Share this with colleagues: // //